Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736485 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL182764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4391706 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4912663 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3155017-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-2709645-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3444281-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | MEDERIS DIABETES LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20200289653-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200277351-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | HERCULES CAPITAL, INC., AS AGENT | 2015-10-15 | — | — | US | disclosed |
| EP-2922877-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| CN-104918961-A | Improved peptide drugs for insulin resistance | MEDERIS DIABETES LLC | 2015-09-16 | — | — | CN | disclosed |
| US-20150031630-A1 | Peptide Pharmaceuticals | HERCULES CAPITAL, INC., AS AGENT | 2015-01-29 | — | — | US | disclosed |
| US-20140349928-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2014081864-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-2710031-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158965-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-1996603-A1 | LIPID A ANTAGONISTS WITH ANTI-SEPTIC SHOCK, ANTI-INFLAMMATORY, ANTI-ISCHEMIA AND ANALGESIC ACTIVITY | Università Degli Studi Di Milano - Bicocca (IT) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107285-A1 | LIPID A ANTAGONISTS WITH ANTI-SEPTIC SHOCK, ANTI-INFLAMMATORY, ANTI-ISCHEMIA AND ANALGESIC ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031630-A1 | Peptide Pharmaceuticals | PTMS, DNPEP, ANPEP | GBA1 1760/4885SLC2A1 4243/4885MAPK1 3194/4885 |
| US-11065304-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-20150290334-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-20140349928-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | GBA1 1762/4885SLC2A1 4046/4885MAPK1 3774/4885 |
| US-20200277351-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | GBA1 2974/4885SLC2A1 125/4885MAPK1 2392/4885 |
| US-20200289653-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, PTMS, GLP1R | GBA1 3108/4885SLC2A1 142/4885MAPK1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.